BR112021026580A2 - Conjugado anticorpo - fármaco, intermediário do mesmo, método de preparação e aplicação do mesmo - Google Patents
Conjugado anticorpo - fármaco, intermediário do mesmo, método de preparação e aplicação do mesmoInfo
- Publication number
- BR112021026580A2 BR112021026580A2 BR112021026580A BR112021026580A BR112021026580A2 BR 112021026580 A2 BR112021026580 A2 BR 112021026580A2 BR 112021026580 A BR112021026580 A BR 112021026580A BR 112021026580 A BR112021026580 A BR 112021026580A BR 112021026580 A2 BR112021026580 A2 BR 112021026580A2
- Authority
- BR
- Brazil
- Prior art keywords
- adc
- application
- drug
- preparation
- same
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 229940127093 camptothecin Drugs 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910577909 | 2019-06-28 | ||
| PCT/CN2020/094767 WO2020259258A1 (zh) | 2019-06-28 | 2020-06-05 | 一种抗体偶联药物、其中间体、制备方法及应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021026580A2 true BR112021026580A2 (pt) | 2022-05-03 |
Family
ID=74059658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021026580A BR112021026580A2 (pt) | 2019-06-28 | 2020-06-05 | Conjugado anticorpo - fármaco, intermediário do mesmo, método de preparação e aplicação do mesmo |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220233708A1 (enExample) |
| EP (1) | EP3991754A4 (enExample) |
| JP (1) | JP7407845B2 (enExample) |
| KR (1) | KR20220025861A (enExample) |
| CN (1) | CN113766933B (enExample) |
| AU (1) | AU2020301289B2 (enExample) |
| BR (1) | BR112021026580A2 (enExample) |
| CA (1) | CA3144790A1 (enExample) |
| WO (1) | WO2020259258A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022011032A2 (pt) * | 2019-12-12 | 2022-08-16 | Jiangsu Hengrui Medicine Co | Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo |
| EP4162954A4 (en) * | 2020-06-08 | 2025-05-07 | SystImmune, Inc. | Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof |
| US20240148889A1 (en) * | 2020-06-11 | 2024-05-09 | President And Fellows Of Harvard College | Stabilized trioxacarcin antibody drug conjugates and uses thereof |
| WO2022078259A1 (zh) * | 2020-10-12 | 2022-04-21 | 四川百利药业有限责任公司 | 一种氘代的喜树碱衍生物及其抗体药物偶联物 |
| EP4257153B1 (en) * | 2020-12-04 | 2025-11-12 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof |
| CN116583526B (zh) * | 2020-12-11 | 2025-09-26 | 微境生物医药科技(上海)有限公司 | 新型喜树碱衍生物、含其的组合物和其用途 |
| JP7564958B2 (ja) * | 2020-12-18 | 2024-10-09 | シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド | Ｂ７－ｈ３を標的とする抗体薬物複合体、その製造方法と使用 |
| AU2020482223A1 (en) * | 2020-12-18 | 2023-07-27 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Trop2 targeting antibody-drug conjugate, and preparation method and use therefor |
| CN114805377A (zh) * | 2021-01-29 | 2022-07-29 | 明慧医药（杭州）有限公司 | 适用于抗体-药物偶联物的毒素分子 |
| WO2022171115A1 (zh) * | 2021-02-09 | 2022-08-18 | 微境生物医药科技(上海)有限公司 | 用于adc制备的喜树碱衍生物 |
| WO2022204947A1 (zh) * | 2021-03-30 | 2022-10-06 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
| CN116867789B (zh) * | 2021-03-31 | 2025-06-24 | 上海复旦张江生物医药股份有限公司 | 一种伊喜替康衍生物的制备方法及其中间体 |
| CN115385926B (zh) * | 2021-05-24 | 2025-06-03 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
| CA3223304A1 (en) * | 2021-06-17 | 2022-12-22 | Minghui Pharmaceutical (Hangzhou) Limited | Antitumor compound and its application |
| IL309884A (en) * | 2021-07-19 | 2024-03-01 | Zeno Man Inc | Immunoconjugates and methods |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| AU2022317608A1 (en) * | 2021-07-30 | 2024-03-14 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Anti-dll3 antibody and preparation method therefor, drug conjugate and application thereof |
| MX2024003277A (es) * | 2021-09-15 | 2024-04-04 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo-farmaco para usarse en metodos de tratamiento del cancer resistente a la quimioterapia. |
| JP2024545138A (ja) * | 2021-12-09 | 2024-12-05 | クンシャン シンユンター バイオテック カンパニー，リミティド | 親和性が改善された抗体薬物複合体、その調製法、及びその応用 |
| JP2025512466A (ja) | 2022-04-12 | 2025-04-17 | ミネルバ バイオテクノロジーズ コーポレーション | 抗可変ｍｕｃ１＊抗体およびその使用 |
| CN118955615A (zh) * | 2022-07-05 | 2024-11-15 | 上海药明合联生物技术有限公司 | 偶联连接子 |
| CA3262616A1 (en) * | 2022-07-22 | 2024-01-25 | Nj Bio, Inc. | HEXACYCLIC TOPOISOMERASE INHIBITORS WITH CYTOTOXIC ACTIVITY ON CANCER CELLS |
| WO2024026323A1 (en) * | 2022-07-26 | 2024-02-01 | Zeno Management, Inc. | Immunoconjugates and methods |
| EP4563163A1 (en) * | 2022-07-27 | 2025-06-04 | Minghui Pharmaceutical (Hangzhou) Limited | Antibody-drug conjugate and use thereof |
| CN117510515A (zh) * | 2022-07-28 | 2024-02-06 | 明慧医药（杭州）有限公司 | 适用于抗体-药物偶联物的毒素分子 |
| JP2025537900A (ja) * | 2022-11-22 | 2025-11-20 | 康諾亜生物医薬科技（成都）有限公司 | 縮合環式化合物及びその複合体並びに使用 |
| AU2023387509A1 (en) * | 2022-11-25 | 2025-07-10 | Minghui Pharmaceutical (Hangzhou) Limited | An anti-tumor compound and use thereof |
| JP2025540696A (ja) * | 2022-11-30 | 2025-12-16 | シャンハイ チア タイ ティエンチン ファーマシューティカル テクノロジー デベロップメント カンパニー リミテッド | 抗ｃｌｄｎ１８．２抗体薬物複合体、その医薬組成物及び使用 |
| CN116217655B (zh) * | 2022-12-30 | 2025-09-23 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的中间体的制备方法 |
| CN116217654B (zh) * | 2022-12-30 | 2025-09-26 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
| CN116178386B (zh) * | 2022-12-30 | 2025-09-09 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
| WO2024214685A1 (ja) | 2023-04-10 | 2024-10-17 | 第一三共株式会社 | 抗ｂ７－ｈ３抗体－薬物コンジュゲートとａｔｒ阻害剤又はａｔｍ阻害剤との組み合わせ |
| WO2025021152A1 (zh) * | 2023-07-26 | 2025-01-30 | 上海医药集团股份有限公司 | 喜树碱类小分子及其抗体药物偶联物、制备方法和应用 |
| TW202515621A (zh) * | 2023-08-25 | 2025-04-16 | 美商宏觀基因有限公司 | Ｂ７—ｈ３抗體藥物偶聯物 |
| WO2025106278A1 (en) | 2023-11-17 | 2025-05-22 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2025238587A1 (en) | 2024-05-16 | 2025-11-20 | Daiichi Sankyo Company, Limited | Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| ES2547552T3 (es) * | 2008-02-01 | 2015-10-07 | Genentech, Inc. | Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos |
| KR101764927B1 (ko) * | 2008-04-30 | 2017-08-03 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| NO2344478T3 (enExample) * | 2008-11-03 | 2018-02-24 | ||
| NZ741211A (en) * | 2012-05-15 | 2019-09-27 | Seattle Genetics Inc | Self-stabilizing linker conjugates |
| IL302494B2 (en) | 2012-10-11 | 2024-11-01 | Daiichi Sankyo Co Ltd | Antibody-drug conjugates and methods for their preparation |
| SMT202500030T1 (it) * | 2014-01-31 | 2025-03-12 | Daiichi Sankyo Co Ltd | Coniugato anticorpo anti-her2-farmaco |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| EP3209334A2 (en) * | 2014-10-20 | 2017-08-30 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
| CA3072500A1 (en) * | 2017-08-10 | 2019-02-14 | Sumitomo Dainippon Pharma Co., Ltd. | Hemiasterlin derivatives and antibody-drug conjugates including same |
| WO2019034176A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| WO2019034177A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 具有两种不同药物的抗体药物偶联物 |
| CN109200291B (zh) * | 2018-10-24 | 2021-06-08 | 中国医学科学院医药生物技术研究所 | 一种靶向于egfr的抗体偶联药物及其制备方法和其用途 |
-
2020
- 2020-06-05 CN CN202080030918.4A patent/CN113766933B/zh active Active
- 2020-06-05 EP EP20833007.6A patent/EP3991754A4/en active Pending
- 2020-06-05 KR KR1020227002873A patent/KR20220025861A/ko not_active Ceased
- 2020-06-05 CA CA3144790A patent/CA3144790A1/en active Pending
- 2020-06-05 AU AU2020301289A patent/AU2020301289B2/en active Active
- 2020-06-05 US US17/622,500 patent/US20220233708A1/en active Pending
- 2020-06-05 WO PCT/CN2020/094767 patent/WO2020259258A1/zh not_active Ceased
- 2020-06-05 JP JP2021578171A patent/JP7407845B2/ja active Active
- 2020-06-05 BR BR112021026580A patent/BR112021026580A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220233708A1 (en) | 2022-07-28 |
| JP7407845B2 (ja) | 2024-01-04 |
| JP2022542222A (ja) | 2022-09-30 |
| EP3991754A4 (en) | 2023-05-17 |
| CN113766933B (zh) | 2024-09-06 |
| WO2020259258A1 (zh) | 2020-12-30 |
| KR20220025861A (ko) | 2022-03-03 |
| EP3991754A1 (en) | 2022-05-04 |
| AU2020301289A1 (en) | 2022-02-24 |
| CA3144790A1 (en) | 2020-12-30 |
| CN113766933A (zh) | 2021-12-07 |
| AU2020301289B2 (en) | 2024-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021026580A2 (pt) | Conjugado anticorpo - fármaco, intermediário do mesmo, método de preparação e aplicação do mesmo | |
| Wang et al. | Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance | |
| Rossignol | Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus | |
| Miyahara et al. | The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma | |
| ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| MX2009011970A (es) | Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos. | |
| DK1061915T3 (da) | Farmaceutiske formuleringer af taxaner | |
| WO2010047765A3 (en) | Nanostructures for drug delivery | |
| CY1119865T1 (el) | Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον | |
| BR112022013150A2 (pt) | Derivado da insulina | |
| UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| ECSP109934A (es) | Compuesto - 946 | |
| CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
| MY159327A (en) | Jak kinase modulating quinazoline derivatives and methods of use thereof | |
| CN106860870A (zh) | 抗肿瘤生物碱的联合治疗 | |
| Destache et al. | Topical tenofovir disoproxil fumarate nanoparticles prevent HIV-1 vaginal transmission in a humanized mouse model | |
| PH12021552362A1 (en) | Estrogen receptor degrading protacs | |
| Alizadeh et al. | Pyrazolotriazines: Biological activities, synthetic strategies and recent developments | |
| Greb et al. | High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. | |
| MX385336B (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| MX383292B (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. | |
| Han et al. | L-securinine induces apoptosis in the human promyelocytic leukemia cell line HL-60 and influences the expression of genes involved in the PI3K/AKT/mTOR signaling pathway | |
| Kwong et al. | Reviving chloroquine for anti-SARS-CoV-2 treatment with cucurbit [7] uril-based supramolecular formulation | |
| EA201290694A1 (ru) | Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы |